The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

The prevalence and incidence of diabetic retinal disease (DRD) has increased in recent years, while the incidence of ...

Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...

Ingelheim, Germany Tuesday, July 8, 2025, 14:00 Hrs [IST] ...

Sources told a media outlet that during the interrogation, Tahawwur Rana shared how he helped David Coleman Headley, the ...

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...

Choi Jun-hee, the daughter of the late actor Choi Jin-sil, revealed her cheekbones and eye plastic surgery reviews.On the 7th ...

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its shares ...

Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...

Netherlands great Vivianne Miedema’s 100th goal in international soccer has been key to a 3-0 win over debut-making Wales at ...

With modern designs and solid function, today’s options show that it’s possible to blend support, comfort, and style into ...